Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: Early results from the prospective randomized AMLSG 09-09 Phase III study
Richard F. Schlenk, Peter Paschka, Julia Krzykalla, Daniela Weber, Silke Kapp-Schwoerer, Verena I. Gaidzik, Claudia Leis, Walter Fiedler, Thomas Kindler, Thomas Schroeder, Karin Mayer, Michael Lübbert, Mohammed Wattad, Katharina Götze, Heinz A. Horst, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Martin Bentz, Richard GreilBernd Hertenstein, Jürgen Krauter, Uwe Martens, David Nachbaur, Maisun Abu Samra, Michael Girschikofsky, Nadezda Basara, Axel Benner, Felicitas Thol, Michael Heuser, Arnold Ganser, Konstanze Döhner, Hartmut Döhner
Research output: Contribution to journal › Article › peer-review
86Scopus
citations
Fingerprint
Dive into the research topics of 'Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: Early results from the prospective randomized AMLSG 09-09 Phase III study'. Together they form a unique fingerprint.